J Manag Care Spec Pharm:对患者来说究竟哪种降压疗法更好?

2017-05-31 枫丹白露 来宝网

诊断为高血压的患者大约一半将在第一年内调整药物,以解决副作用或未能正确控制血压的情况。根据佛罗里达大学研究员领导的新研究,在可用的修改方案中,一种药物治疗与后续医生访问和住院费用相关。


【一种更经济的降压药疗法】诊断高血压的患者大约一半将在第一年内调整药物,以解决副作用或未能正确控制血压的情况。根据佛罗里达大学研究员领导的新研究,在可用的修改方案中,一种药物治疗与后续医生访问和住院费用相关。

研究结果发表在“管理护理药剂学杂志”六月刊上。

该研究增加了首席研究员Kalyani Sonawane博士的研究结果,证明结合了一种药物的疗法,称为固定剂量组合,具有优于其他调整血压药物的方法。固定剂量联合治疗的患者更有可能继续服用他们的药物,更有可能按照医师的指示服用它们。其他机构的临床试验也显示,与其他药物疗法相比,固定剂量组合在控制高血压方面效应几乎高出五倍。

UF公立卫生和健康专业学院卫生服务研究,管理和政策的临床助理教授Sonawane说:“每个人都是双赢的局面。 “从患者和医师的角度来看,您可以通过固定剂量组合获得更高的疗效,并且患者在药物上会持续使用更长时间并且具有更好的依从性。从管理型医疗机构的观点来看,您可以获得较低的医疗服务费用”。

几乎三分之一的美国人患有高血压,这使得他们患中风和心脏病的风险增加。在治疗血压的患者中,约30%有副作用问题,近50%的患者在服用药物的第一年内不能控制血压。在这一点上,医生有几种方法来调整患者的血压。这些包括向患者的方案中加入药物,例如固定剂量组合,逐渐增加患者目前药物的剂量,逐渐降低其目前药物的剂量或将患者的处方转为不同的药物。

在一系列研究中,Sonawane也是通过培训的药剂师,在血压药物调整期间评估了医生的处方模式和患者结果。在她目前的研究中,她研究了与不同药物修改策略相关的成本。

Sonawane及其团队分析了2008年至2012年期间德克萨斯商业索赔数据库BlueCross BlueShield的数据。他们跟踪了保险公司每年的药物成本和门诊及住院病人相关的卫生服务费用,为约6000名患有高血压的患者进行了药物调整。

固定剂量组合是最昂贵的药物治疗方式,每年平均花费310美元的患者健康保险计划,而转用新药则为135美元,逐渐增加当前药物剂量为63美元,使用目前的药物逐渐减少61美元。

但固定剂量组合患者的后续保健费用最低。与血压或心血管事件相关的卫生服务费用,固定剂量组合患者平均为1731美元,而用药量减少的患者为2,985美元,转为新型血压药物的患者为7,076美元,增加剂量患者为7,692美元。

Sonawane说,一些医生不愿意向患者开出固定剂量组合,药物治疗费用是该决定的其中一个因素。她希望她的研究提供证据,证明长期的成本节约是由较少的后续保健需求以及药物的有效性和患者依从性的改善等引起的。

Sonawane说:“即使固定剂量组合的药物成本似乎非常高,它被卫生服务成本节省抵消,节省了住院费用的七倍。”

原始出处

Kalyani B. Sonawane Deshmukh, Jingjing Qian, Kimberly B. Garza, et al. Health Care Costs Associated with Addition, Titration, and Switching Antihypertensive Medications After First-Line Treatment: Results from a Commercially Insured Sample. J Manag Care Spec Pharm, 2017 Jun;23(6):691-699.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1787258, encodeId=db7d1e8725865, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Aug 07 21:42:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633371, encodeId=a38b16333e1b6, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Thu Oct 05 21:42:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726449, encodeId=7eec1e2644978, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 17 21:42:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291911, encodeId=44a8129191161, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Fri Jun 02 11:42:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205511, encodeId=be6420551140, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Fri Jun 02 08:03:27 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205484, encodeId=dbe52054844a, content=学习了,分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Fri Jun 02 07:11:12 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205482, encodeId=e4f22054828f, content=学习了分亨, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Fri Jun 02 07:10:49 CST 2017, time=2017-06-02, status=1, ipAttribution=)]
    2017-08-07 jj000001
  2. [GetPortalCommentsPageByObjectIdResponse(id=1787258, encodeId=db7d1e8725865, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Aug 07 21:42:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633371, encodeId=a38b16333e1b6, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Thu Oct 05 21:42:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726449, encodeId=7eec1e2644978, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 17 21:42:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291911, encodeId=44a8129191161, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Fri Jun 02 11:42:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205511, encodeId=be6420551140, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Fri Jun 02 08:03:27 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205484, encodeId=dbe52054844a, content=学习了,分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Fri Jun 02 07:11:12 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205482, encodeId=e4f22054828f, content=学习了分亨, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Fri Jun 02 07:10:49 CST 2017, time=2017-06-02, status=1, ipAttribution=)]
    2017-10-05 AspirantSuo
  3. [GetPortalCommentsPageByObjectIdResponse(id=1787258, encodeId=db7d1e8725865, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Aug 07 21:42:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633371, encodeId=a38b16333e1b6, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Thu Oct 05 21:42:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726449, encodeId=7eec1e2644978, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 17 21:42:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291911, encodeId=44a8129191161, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Fri Jun 02 11:42:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205511, encodeId=be6420551140, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Fri Jun 02 08:03:27 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205484, encodeId=dbe52054844a, content=学习了,分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Fri Jun 02 07:11:12 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205482, encodeId=e4f22054828f, content=学习了分亨, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Fri Jun 02 07:10:49 CST 2017, time=2017-06-02, status=1, ipAttribution=)]
    2017-06-17 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=1787258, encodeId=db7d1e8725865, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Aug 07 21:42:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633371, encodeId=a38b16333e1b6, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Thu Oct 05 21:42:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726449, encodeId=7eec1e2644978, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 17 21:42:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291911, encodeId=44a8129191161, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Fri Jun 02 11:42:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205511, encodeId=be6420551140, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Fri Jun 02 08:03:27 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205484, encodeId=dbe52054844a, content=学习了,分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Fri Jun 02 07:11:12 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205482, encodeId=e4f22054828f, content=学习了分亨, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Fri Jun 02 07:10:49 CST 2017, time=2017-06-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1787258, encodeId=db7d1e8725865, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Aug 07 21:42:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633371, encodeId=a38b16333e1b6, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Thu Oct 05 21:42:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726449, encodeId=7eec1e2644978, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 17 21:42:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291911, encodeId=44a8129191161, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Fri Jun 02 11:42:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205511, encodeId=be6420551140, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Fri Jun 02 08:03:27 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205484, encodeId=dbe52054844a, content=学习了,分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Fri Jun 02 07:11:12 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205482, encodeId=e4f22054828f, content=学习了分亨, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Fri Jun 02 07:10:49 CST 2017, time=2017-06-02, status=1, ipAttribution=)]
    2017-06-02 lou.minghong

    学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1787258, encodeId=db7d1e8725865, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Aug 07 21:42:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633371, encodeId=a38b16333e1b6, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Thu Oct 05 21:42:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726449, encodeId=7eec1e2644978, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 17 21:42:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291911, encodeId=44a8129191161, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Fri Jun 02 11:42:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205511, encodeId=be6420551140, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Fri Jun 02 08:03:27 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205484, encodeId=dbe52054844a, content=学习了,分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Fri Jun 02 07:11:12 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205482, encodeId=e4f22054828f, content=学习了分亨, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Fri Jun 02 07:10:49 CST 2017, time=2017-06-02, status=1, ipAttribution=)]
    2017-06-02 杨利洪

    学习了,分享了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1787258, encodeId=db7d1e8725865, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Aug 07 21:42:00 CST 2017, time=2017-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633371, encodeId=a38b16333e1b6, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Thu Oct 05 21:42:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726449, encodeId=7eec1e2644978, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jun 17 21:42:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291911, encodeId=44a8129191161, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Fri Jun 02 11:42:00 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205511, encodeId=be6420551140, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Fri Jun 02 08:03:27 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205484, encodeId=dbe52054844a, content=学习了,分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Fri Jun 02 07:11:12 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205482, encodeId=e4f22054828f, content=学习了分亨, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Fri Jun 02 07:10:49 CST 2017, time=2017-06-02, status=1, ipAttribution=)]
    2017-06-02 杨利洪

    学习了分亨

    0

相关资讯

我国糖尿病患者达1.14亿!但降压比降糖更重要

近日,由北京大学糖尿病中心、《中国糖尿病杂志》社联合主办的“2017北大糖尿病论坛”在北京举办。今年的主题是“糖尿病药物治疗新进展——从分子到策略”。糖尿病并发症中死亡率最高的就是心血管病变!挑战:血压升高会增心血管风险我国已确诊的糖友达1.14亿,然而2010年我国的高血压患者就已经超过了2亿!我国不仅是个糖尿病大国,也是一个高血压的大国。广东省人民医院心血管内科主任医师陈纪言表示:“有资料显示

LANCET:高血压治疗新概念——quadpill!

全球范围内,大多数患有高血压的患者用单一疗法治疗,并且对血压的控制效果很差,因为单一疗法平均仅将血压降低约9 / 5mmHg。因此,迫切需要具有改善功效和耐受性的血压控制策略。近期,一项发表在杂志LANCET上的研究旨在评估超低剂量药物联合治疗是否可以满足这些需求。研究者们做了一个随机、安慰剂对照、双盲、交叉试验的quadpill-单个胶囊含四种降血压药物,每中药物含量为常规四分之一剂量(厄贝沙坦

更有效的降压降脂食物!

本文专家观点: 北京大学第一医院老年病内科刘梅林教授 大鱼大肉等油腻食物吃多了,很容易导致一种危险的指数超标! 坏胆固醇是心脑血管疾患致病元凶!有研究数据显示,中国居民冠心病死亡率增加,77%是由于血液胆固醇升高所引起! 坏的胆固醇,指低密度脂蛋白胆固醇(LDL-C),如果坏胆固醇过高,动脉粥样硬化斑块也就越多,继而导致血管狭窄,长期不加重视,随时都可能引发心梗、脑卒中、突发性猝死等心血管疾病。

J Am Geriatrics Soc:老年患者降压,只有“衰弱”者血压才应≥150/90 mmHg

既往研究已证实,高血压可导致死亡风险增加。但美国一项研究表明,血压≥150 /90 mmHg的虚弱老人,死亡风险较低,尤其是握力较弱且走路慢者。 女性握力<16 kg、男性<26 kg视为握力较弱,反之则握力正常;走路慢是指女性步行速度<0.6米/秒,男性<0.52米/秒,反之走路不慢。 校正混淆因素后,在握力较弱的老年人中,收缩压和舒张压升高的人,死亡风险分别

J Hypertens:降压同时添加叶酸降低肾病相关死亡风险

日发布的CSPPT亚组研究数据显示,大量蛋白尿以及肾小球滤过率降低显着增加高血压患者的死亡风险。

Circulation:强化降低血压对高血压患者左心室肥厚的影响!

目前尚不清楚超出推荐值的强化血压(BP)降低是否会导致高血压患者的左心室肥大(LVH)风险降低;也尚不清楚,LVH的风险降低是否可以解释在这个人群中所报告的对心血管疾病( CVD)的益处。近期,一项发表在杂志Circulation上的研究分析了8,164名具有高血压但无糖尿病的参与者(平均年龄67.9岁,女性35.3%,31.2%黑人)的收缩期血压干预(SPRINT)试验;4,086名参与者随机分